down arrow

Century Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US15673T1007
USD
1.67
-0.02 (-1.18%)

Sep 25

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Prelude Therapeutics, Inc.
Vaxart, Inc.
TScan Therapeutics, Inc.
Trevi Therapeutics, Inc.
Design Therapeutics, Inc.
Century Therapeutics, Inc.
Greenwich LifeSciences, Inc.
Galectin Therapeutics, Inc.
XBiotech, Inc.
INmune Bio, Inc.
BioVie, Inc.

Why is Century Therapeutics, Inc. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is Century Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Century Therapeutics, Inc.
242.42%
-0.50
99.81%
S&P 500
17.24%
1.31
13.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
156.10%
EBIT Growth (5y)
11.12%
EBIT to Interest (avg)
-74.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.67
Sales to Capital Employed (avg)
0.24
Tax Ratio
8.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.50%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.28
EV to EBIT
-16.53
EV to EBITDA
-128.53
EV to Capital Employed
5.60
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-33.90%
ROE (Latest)
-4.62%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -86.73 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-11What is not working for the Company
NET PROFIT(HY)

At USD -48.81 MM has Grown at -210.51%

CASH AND EQV(HY)

Lowest at USD 254.87 MM

DEBT-EQUITY RATIO (HY)

Highest at -34.88 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

Here's what is working for Century Therapeutics, Inc.

Operating Cash Flow
Highest at USD -86.73 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Century Therapeutics, Inc.

Net Profit
At USD -48.81 MM has Grown at -210.51%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 254.87 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at -34.88 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading